College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.
Gynecol Oncol. 2011 Oct;123(1):152-6. doi: 10.1016/j.ygyno.2011.06.039. Epub 2011 Jul 20.
Gynaecological cancer is common. It is highly amenable to effective treatment, but thrombosis remains a common complication. There is controversy about whether microparticles (MPs), particularly tissue factor (TF) positive MPs, are increased in patients with malignancy and/or thrombosis. We therefore set out to investigate the relationship between MPs of different cellular origins, in patients with gynaecological malignancy. We hypothesised that patients with gynaecological malignancy have increased numbers of MPs. We measured MPs released by different cell types in these patients, and correlated the results with measures of haemostatic activation.
We measured the number of platelet-derived MPs (PMPs), endothelial cell-derived MPs (EMPs), leucocyte-derived MPs (LMPs), TF+ve MPs and annexin V (AV) binding MPs in fresh plasma by flow cytometry in patients with gynaecological malignancy and a control group. We also measured D-dimers, prothrombin fragments 1 and 2 (PF1&2) and thrombin-antithrombin (TAT) complexes as indirect markers of haemostatic activation.
The number of MPs (from all cell types) was similar in the two patient groups, with no significant differences. The number of circulating TF+ve MPs was also similar between the two groups. D-dimers (p<0.001) and PF1&2 (p=0.009) were significantly higher in the malignant group reflecting haemostatic activation, but there was no correlation between the level of D-dimers, PF1&2 and TAT and MP numbers.
Using fresh samples, MPs were not significantly increased in patients with gynaecological malignancy. There was, however, evidence of haemostatic activation in the patients with malignancy, but no correlation between the number of MPs and haemostatic activation.
妇科癌症很常见。它对有效治疗高度敏感,但血栓仍然是常见的并发症。关于恶性肿瘤和/或血栓形成患者是否会增加微粒(MPs),特别是组织因子(TF)阳性 MPs,存在争议。因此,我们着手研究妇科恶性肿瘤患者不同细胞来源的 MPs 之间的关系。我们假设妇科恶性肿瘤患者的 MPs 数量增加。我们测量了这些患者不同细胞类型释放的 MPs,并将结果与止血激活的测量值相关联。
我们通过流式细胞术测量了妇科恶性肿瘤患者和对照组新鲜血浆中血小板衍生 MPs(PMPs)、内皮细胞衍生 MPs(EMPs)、白细胞衍生 MPs(LMPs)、TF+ve MPs 和膜联蛋白 V(AV)结合 MPs 的数量。我们还测量了 D-二聚体、凝血酶原片段 1 和 2(PF1&2)和凝血酶-抗凝血酶(TAT)复合物作为止血激活的间接标志物。
两组患者的 MPs(来自所有细胞类型)数量相似,无显着差异。两组循环 TF+ve MPs 的数量也相似。恶性肿瘤组的 D-二聚体(p<0.001)和 PF1&2(p=0.009)显着升高,反映出止血激活,但 D-二聚体、PF1&2 和 TAT 与 MPs 数量之间没有相关性。
使用新鲜样本,妇科恶性肿瘤患者的 MPs 没有显着增加。然而,恶性肿瘤患者存在止血激活的证据,但 MPs 数量与止血激活之间没有相关性。